Drug pricing simulator

This one has many moving parts. What the simulator demonstrates:

1. Target price range

2. HTA acceptability

$$\text{ICER} = \frac{\text{Drug cost} – \text{costs avoided}} {\text{incremental health benefit}}$$

3. Comparator sensitivity

4. Indication-specific pricing

5. Population restriction

6. Evidence uncertainty

7. Net price and rebate modelling

$$\text{Net price} = \text{List price} – \text{mandatory discounts} – \text{rebates} – \text{commercial concessions}$$

8. Budget impact

9. Country comparison

10. Launch sequencing

11. Negotiation scenarios

12. Evidence-development priorities

Which additional evidence is most likely to increase the achievable price?

Here is an interactive overview of the simulator.